Modified vaccinia Ankara - Bavarian Nordic
Alternative Names: IMVAMUNE; IMVAMUNE® liquid-frozen; IMVAMUNE® freeze-dried; IMVANEX; JYNNEOS; Monkeypox vaccine - Bavarian Nordic; MVA-BN; MVA-BN® Smallpox; MVA-BN® freeze-dried; MVA-BN® liquid-frozen; MVA-BN® smallpox vaccine; Smallpox and monkeypox vaccine - Bavarian NordicLatest Information Update: 10 Oct 2025
At a glance
- Originator Bavarian Nordic
- Developer Bavarian Nordic; Centers for Disease Control and Prevention; Coalition for Epidemic Preparedness Innovations; National Institute of Allergy and Infectious Diseases; National Institutes of Health (USA)
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Monkeypox; Smallpox; Vaccinia virus infections
- Phase II Orthopoxvirus infections
Most Recent Events
- 07 Oct 2025 Bavarian Nordic announces intention to submit MAA to EMA for Orthopox virus, Smallpox and Monkey pox (In Children, In adolescent, Prevention) in 2026
- 30 Sep 2025 Bavarian Nordic plans a phase II trial for Monkeypox in October 2025 (SC) (NCT07199569)
- 29 May 2025 Phase-III clinical trials in Monkeypox (In infants, Prevention) in Democratic Republic of the Congo (SC) (NCT06844487)